572 related articles for article (PubMed ID: 32076273)
21. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer.
Zhao J; Wen X; Tian L; Li T; Xu C; Wen X; Melancon MP; Gupta S; Shen B; Peng W; Li C
Nat Commun; 2019 Feb; 10(1):899. PubMed ID: 30796212
[TBL] [Abstract][Full Text] [Related]
22. Sepsis Induces Deregulation of IL-13 Production and PD-1 Expression in Lung Group 2 Innate Lymphoid Cells.
Akama Y; Park EJ; Satoh-Takayama N; Gaowa A; Ito A; Kawamoto E; Darkwah S; Appiah MG; Myint PK; Ohno H; Imai H; Shimaoka M
Shock; 2021 Mar; 55(3):357-370. PubMed ID: 32826811
[TBL] [Abstract][Full Text] [Related]
23. IL-33-ILC2 axis promotes anti-tumor CD8
Okuyama Y; Okajima A; Sakamoto N; Hashimoto A; Tanabe R; Kawajiri A; Kawabe T; Ishii N
Biochem Biophys Res Commun; 2022 Dec; 637():9-16. PubMed ID: 36375254
[TBL] [Abstract][Full Text] [Related]
24. Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients.
Oberg HH; Grage-Griebenow E; Adam-Klages S; Jerg E; Peipp M; Kellner C; Petrick D; Gonnermann D; Freitag-Wolf S; Röcken C; Sebens T; Vogel I; Becker T; Ebsen M; Kabelitz D; Wesch D; Sebens S
Pancreatology; 2016; 16(6):1069-1079. PubMed ID: 27424476
[TBL] [Abstract][Full Text] [Related]
25. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer.
Fan P; Zhao J; Meng Z; Wu H; Wang B; Wu H; Jin X
J Exp Clin Cancer Res; 2019 Feb; 38(1):47. PubMed ID: 30709380
[TBL] [Abstract][Full Text] [Related]
26. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
[TBL] [Abstract][Full Text] [Related]
27. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
[TBL] [Abstract][Full Text] [Related]
28. A Disintegrin and Metalloproteinase 17 is required for ILC2 responses to IL-33.
Lownik JC; Conrad DH; Martin RK
Biochem Biophys Res Commun; 2019 May; 512(4):723-728. PubMed ID: 30926166
[TBL] [Abstract][Full Text] [Related]
29. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
[TBL] [Abstract][Full Text] [Related]
30. IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer.
Mirlekar B; Michaud D; Searcy R; Greene K; Pylayeva-Gupta Y
Cancer Immunol Res; 2018 Sep; 6(9):1014-1024. PubMed ID: 29980536
[TBL] [Abstract][Full Text] [Related]
31. Interferon-γ constrains cytokine production of group 2 innate lymphoid cells.
Kudo F; Ikutani M; Seki Y; Otsubo T; Kawamura YI; Dohi T; Oshima K; Hattori M; Nakae S; Takatsu K; Takaki S
Immunology; 2016 Jan; 147(1):21-9. PubMed ID: 26425820
[TBL] [Abstract][Full Text] [Related]
32. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
33. Targeting both tumour-associated CXCR2
Nywening TM; Belt BA; Cullinan DR; Panni RZ; Han BJ; Sanford DE; Jacobs RC; Ye J; Patel AA; Gillanders WE; Fields RC; DeNardo DG; Hawkins WG; Goedegebuure P; Linehan DC
Gut; 2018 Jun; 67(6):1112-1123. PubMed ID: 29196437
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1.
Wang K; Zhan Y; Huynh N; Dumesny C; Wang X; Asadi K; Herrmann D; Timpson P; Yang Y; Walsh K; Baldwin GS; Nikfarjam M; He H
Cancer Lett; 2020 Mar; 472():8-18. PubMed ID: 31857154
[TBL] [Abstract][Full Text] [Related]
35. Leukotriene C4 Potentiates IL-33-Induced Group 2 Innate Lymphoid Cell Activation and Lung Inflammation.
Lund SJ; Portillo A; Cavagnero K; Baum RE; Naji LH; Badrani JH; Mehta A; Croft M; Broide DH; Doherty TA
J Immunol; 2017 Aug; 199(3):1096-1104. PubMed ID: 28667163
[TBL] [Abstract][Full Text] [Related]
36. PPARɣ drives IL-33-dependent ILC2 pro-tumoral functions.
Ercolano G; Gomez-Cadena A; Dumauthioz N; Vanoni G; Kreutzfeldt M; Wyss T; Michalik L; Loyon R; Ianaro A; Ho PC; Borg C; Kopf M; Merkler D; Krebs P; Romero P; Trabanelli S; Jandus C
Nat Commun; 2021 May; 12(1):2538. PubMed ID: 33953160
[TBL] [Abstract][Full Text] [Related]
37. Viro-immune therapy: A new strategy for treatment of pancreatic cancer.
Ibrahim AM; Wang YH
World J Gastroenterol; 2016 Jan; 22(2):748-63. PubMed ID: 26811622
[TBL] [Abstract][Full Text] [Related]
38. Sex differences in group 2 innate lymphoid cell-dominant allergic airway inflammation.
Wang C; Xu ZB; Peng YQ; Zhang HY; Yu QN; Guo YB; Tan WP; Liu YL; Meng XC; Fang SB; Chen D; Fu QL
Mol Immunol; 2020 Dec; 128():89-97. PubMed ID: 33096416
[TBL] [Abstract][Full Text] [Related]
39. Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer.
Zhao J; Xiao Z; Li T; Chen H; Yuan Y; Wang YA; Hsiao CH; Chow DS; Overwijk WW; Li C
ACS Nano; 2018 Oct; 12(10):9881-9893. PubMed ID: 30231203
[TBL] [Abstract][Full Text] [Related]
40. Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tumor microenvironment.
Osborne N; Sundseth R; Burks J; Cao H; Liu X; Kroemer AH; Sutton L; Cato A; Smith JP
Cancer Immunol Immunother; 2019 Oct; 68(10):1635-1648. PubMed ID: 31549214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
